DrugDashboards

Urogesic Blue

METHENAMINE, SODIUM PHOSPHATE, MONOBASIC, METHYLENE BLUE, and HYOSCYAMINE SULFATE · METHENAMINE 81.6 mg/1; SODIUM PHOSPHATE, MONOBASIC 40.8 mg/1; METHYLENE BLUE 10.8 mg/1; HYOSCYAMINE SULFATE .12 mg/1 · Tablet, Coated · Oral · Edwards Pharmaceuticals, Inc.

NDC 00485-0151-01 · 100 TABLET, COATED in 1 BOTTLE, PLASTIC · UNAPPROVED DRUG OTHER · View full market →

The short version

Only one company currently supplies this market — there is no backup if it stumbles. The price has held steady around $4.01 per unit over the past year. Put together: worth watching — several of the pressures that precede supply trouble are present at once.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$2.00$4.00$6.00Nov 2013Sep 2026$4.01
130 price points · per EASource: CMS NADAC

Estimated fill cost

#30 count
$120.35
#90 count
$361.04

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Medicaid spend (2025)

$39,628
133 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

30Elevated risk

The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.

  • 1 active manufacturer+30

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for methenamine, sodium phosphate, monobasic, methylene blue, and hyoscyamine sulfate (oral solid) in the next 90 days

price up 4% YoY

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Regulatory

Application
TE code
Approval date
Patents / exclusivity

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of METHENAMINE, SODIUM PHOSPHATE, MONOBASIC, METHYLENE BLUE, and HYOSCYAMINE SULFATE (Tablet, Coated)

LabelerStrengthFirst seenLast seen
Edwards Pharmaceuticals, Inc.METHENAMINE 81.6 mg/1; SODIUM PHOSPHATE, MONOBASIC 40.8 mg/1; METHYLENE BLUE 10.8 mg/1; HYOSCYAMINE SULFATE .12 mg/1Aug 26, 2026Sep 2, 2026
Edwards Pharmaceuticals, Inc.METHENAMINE .12 mg/1; SODIUM PHOSPHATE, MONOBASIC 81.6 mg/1; METHYLENE BLUE 10.8 mg/1; HYOSCYAMINE SULFATE 40.8 mg/1Jul 22, 2026Aug 19, 2026
Edwards Pharmaceuticals, Inc.HYOSCYAMINE SULFATE .12 mg/1; METHENAMINE 81.6 mg/1; METHYLENE BLUE 10.8 mg/1; SODIUM PHOSPHATE, MONOBASIC 40.8 mg/1Jul 15, 2026Jul 16, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Urogesic Blue — NDC 00485-0151-01," retrieved September 3, 2026, https://drugdashboards.com/drug/00485015101.

Free to cite with attribution — see how the data is put together.